Pharma BD Deal Intelligence

Eli Lilly and Company / Calytrix Bio

2026 · Acquisition/Merger · $1.5B · Pending

Eli Lilly agreed to acquire Calytrix Bio, a preclinical-stage biotech in Wellesley Hills, Massachusetts developing precision, disease-modifying therapies for myeloproliferative neoplasms. Calytrix shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment plus subsequent payments contingent on achievement of certain clinical and regulatory milestones. Calytrix's lead program is a biparatopic antibody designed to target both Type 1 and Type 2 mutant calreticulin (mCALR), the driver mutation in a subset of patients with essential thrombocythemia and myelofibrosis. The company was founded by J.P. Morgan Life Sciences Private Capital, with Westlake BioPartners co-leading its Series A and Avoro Ventures leading its Series B. Lilly's stated aim is to alter disease course in mCALR-driven ET and MF rather than manage symptoms.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →